Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech (Nasdaq: EDSA) priced an underwritten public offering of (i) 3,870,500 common shares with accompanying common share warrants and (ii) pre-funded warrants to purchase up to 675,000 common shares, each paired with a common share warrant. Each common share unit is priced at $5.50, and each pre-funded warrant unit at $5.4999, reflecting a pre-funded warrant exercise price of $0.0001 per share.
The common share warrants have an exercise price of $7.50 per share, are immediately exercisable, and will expire on the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06. Gross proceeds are expected to be approximately $25.0 million before fees. The company granted underwriters a 30-day option to buy up to an additional 681,825 common shares and accompanying warrants. Closing is expected on or about August 21, 2026, with Guggenheim Securities as sole book-runner. Edesa plans to use net proceeds for general corporate purposes, including working capital, capital expenditures, and R&D and manufacturing expenses.
Edesa Biotech (Nasdaq: EDSA) has commenced an underwritten public offering of common shares (or pre-funded warrants in lieu thereof) together with accompanying common share warrants. Edesa expects to grant underwriters a 30-day option to purchase up to 15% additional common shares, pre-funded warrants and accompanying warrants on the same terms. All securities in the transaction will be offered by the company.
The size and pricing of the proposed offering remain subject to market and other conditions. Guggenheim Securities is acting as sole book-running manager. Edesa plans to use net proceeds for general corporate purposes, including working capital, capital expenditures, and research, development and manufacturing expenses. The deal is being made under an effective Form S-3 shelf registration statement declared effective on September 9, 2025.
Edesa Biotech (Nasdaq: EDSA) reported fiscal third quarter 2026 results and business updates for the periods ended June 30, 2026. The company completed preparations for its Phase 2 EB06 vitiligo trial during the quarter and, after quarter-end, began activating initial investigational sites, with patient recruitment expected to start in the coming weeks in Canada, subject to regulatory and administrative approvals.
In its respiratory program, additional exploratory analyses in ARDS patients with concurrent acute kidney injury showed paridiprubart plus standard of care was associated with significant mortality reductions and improvements in the kidney-specific MAKE30 endpoint. Operating expenses rose to $5.5 million in Q3 and $12.2 million year-to-date, driving net losses of $5.4 million (Q3) and $11.9 million (nine months). Edesa reported $10.3 million in cash and cash equivalents and working capital of $6.9 million at June 30, 2026.
Edesa Biotech (Nasdaq: EDSA) entered a securities purchase agreement for a PIPE financing expected to raise approximately $3.5 million in gross proceeds. The deal covers 729,241 common shares at $4.69 per share for investors and $5.21 for the CEO.
The private placement, led by the CEO and healthcare-focused investors, is expected to close on or about June 15, 2026, subject to customary conditions. Edesa plans to use net proceeds to advance its vitiligo program, its drug candidate paridiprubart, and for working capital and general corporate purposes. The company agreed to file an SEC resale registration statement within 45 days of closing.
Edesa Biotech (Nasdaq: EDSA) reported exploratory post hoc data for paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress, drawn from prior Phase 2/3 ARDS studies.
Paridiprubart plus standard of care was associated with lower adjusted 28‑day mortality and MAKE30 incidence, with a safety profile comparable to placebo. Results are exploratory and require confirmatory studies.
Edesa Biotech (Nasdaq: EDSA) will deliver an oral presentation on paridiprubart, a first-in-class anti-TLR4 antibody, at the 63rd European Renal Association Congress in Glasgow, June 3–6, 2026.
The June 5 talk covers exploratory Phase 3 data in acute kidney injury with respiratory distress and additional analyses.
Edesa Biotech (Nasdaq: EDSA) reported fiscal Q2 2026 results and clinical updates. The company advanced preparations for a Phase 2 study of EB06 in vitiligo and reported additional positive Phase 3 data for paridiprubart in ARDS.
Q2 operating expenses were $4.3M, with a net loss of $4.2M ($0.49/share). For the six months, net loss was $6.5M ($0.78/share). Edesa ended March 31, 2026 with $10.0M in cash and $8.2M in working capital.
Edesa Biotech (Nasdaq: EDSA) announced oral and poster presentations of its Phase 3 paridiprubart (EB05) data at ATS 2026 events. Dr. Par Nijhawan will present at the Respiratory Innovation Summit on May 15, 2026, and a full oral presentation occurs on May 20, 2026.
Two Phase 3 data sets were described: an initial 104-patient IMV cohort and expanded 278-patient results including IMV and non-IMV patients, with reported statistically significant mortality reductions for ARDS patients.
Edesa Biotech (Nasdaq:EDSA) updated progress on its Phase 2 study of EB06 for moderate-to-severe nonsegmental vitiligo and reaffirmed a mid-2026 timeline for site activations and patient recruitment.
The company selected JSS Medical Research as CRO, began outreach to sites and investigators, and noted its Canadian clinical trial application was approved, with enrollment to start first in Canada pending any required administrative protocol filings.
Edesa Biotech (Nasdaq:EDSA) reported positive additional Phase 3 results for paridiprubart in 278 randomized ARDS patients. Adjusted 28-day mortality fell to 24% versus 33% with placebo (27% relative reduction, p<0.001). Non-IMV patients saw mortality drop to 15% from 23% (35% relative reduction, p<0.05).
Exploratory subgroup reductions included acute kidney injury, sepsis and pneumonia; safety was similar between arms. Edesa filed provisional US patent applications for these indications and plans regulatory discussions, manufacturing scale-up and strategic collaborations.